Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial

被引：0
|
作者：
Lipton, Richard B. [1 ]
Ashina, Messoud [2 ]
Tassorelli, Cristina [3 ]
Martin, Vincent [4 ]
Yu, Sung Y. [5 ]
Nagy, Krisztian [6 ]
Schwefel, Brittany [7 ]
Trugman, Joel [5 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] Univ Copenhagen, Dept Neurol, Danish Headache Ctr, Rigshospitalet Glostrup, Cophenhagen, Denmark
[3] C Mondino Fdn & Univ Pavia, Headache Sci Ctr, Pavia, Italy
[4] Univ Cincinnati, Cincinnati, OH USA
[5] AbbVie, Madison, NJ USA
[6] AbbVie, Budapest, Hungary
[7] AbbVie, N Chicago, IL USA
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-EP-
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [1] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, R.
    Ashina, M.
    Tassorelli, C.
    Martin, V.
    Yu, S. Y.
    Nagy, K.
    Schwefel, B.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [2] Atogepant for the preventive treatment of chronic migraine: Results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Goadsby, P. J.
    HEADACHE, 2022, 62 (07): : 923 - 923
  • [3] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    Goadsby, P.
    Lipton, R.
    Reuter, U.
    Guo, H.
    Schwefel, B.
    Boinpally, R.
    McCusker, E.
    Yu, S. Yun
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [4] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter J.
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 14 - 15
  • [5] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    NEUROLOGY, 2023, 100 (17)
  • [6] Early Onset of Efficacy With Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Ailani, Jessica
    Reuter, Uwe
    Graboski, Corrie
    Klein, Brad C.
    Yu, Sung Y.
    Nagy, Krisztian
    Guo, Hua
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 32 - 33
  • [7] Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
    Goadsby, P.
    Pozo-Rosich, P.
    Ashina, M.
    Reuter, U.
    Moisset, X.
    Trugman, J.
    Ha, H.
    Schwefel, B.
    Nagy, K.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [8] Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
  • [9] Atogepant, the first oral preventive treatment for chronic migraine
    Haanes, Kristian A.
    Edvinsson, Lars
    LANCET, 2023, 402 (10404): : 748 - 749
  • [10] Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 159
12345